Advanced Glycosylation End Product-Specific Receptor (AGER) Antibody

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Advanced Glycosylation End Product-Specific Receptor (AGER) Antibody is a Rabbit polyclonal antibody for the detection of Human Advanced Glycosylation End Product-Specific Receptor (AGER).
Documents del producto
Product specifications
Category | Primary Antibodies |
Immunogen Target | Advanced Glycosylation End Product-Specific Receptor (AGER) |
Host | Rabbit |
Reactivity | Human |
Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
Clonality | Polyclonal |
Conjugation | Unconjugated |
Isotype | IgG |
Size 1 | 50 µg |
Size 2 | 100 µg |
Form | Liquid |
Tested Applications | ELISA, WB, IHC |
Buffer | 0.01 M PBS, pH 7.4, 50% glycerol, 0.05% Proclin-300. |
Availability | Shipped within 5-12 working days. |
Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
Dry Ice | No |
UniProt ID | Q15109 |
Gene ID | 177 |
NCBI Accession | NP_001127.1 |
Alias | RAGE,SCARJ1,sRAGE |
Background | Antibody anti-AGER |
Status | RUO |
Descripción
Related Products

Mouse AGER(Advanced Glycosylation End Product Specific Receptor) ELISA Kit
Ver Producto
anti- AGER antibody
Mediates interactions of advanced glycosylation end products(AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling(By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide(ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase(MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides.
Ver Producto
anti- AGER antibody
Mediates interactions of advanced glycosylation end products(AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling(By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide(ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase(MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides.
Ver Producto